Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings

23 May 2018

• By Malcolm Spicer

FDAEntrance_1200x675

Related Content

DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

14 Oct 2016

Kratom: All Questions On Pre-DSHEA Ingredient Evidence In One Package

16 Oct 2017

FDA's Opioid Label For Kratom Called Misbranding By Marketers

07 Feb 2018

Las Vegas Kratom Marketer Rolls Dice On FDA's Mandatory Recall Authority

03 Apr 2018

AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

30 Apr 2018

Additional Topics

United States Dietary Supplements Safety FDA Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.